ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinicopathological characteristics of HER2-low breast cancer: a retrospective study

Yang, Man; Sun, Jiale; Liu, Liqiong; Kong, Xiangyi; Lin, Dongcai; Zhou, Hong; Gao, Jidong*南方医科大学; 中国医学科学院; 中国医学科学院北京协和医院
Scientific Reports2023-7-18DOI: 10.1038/s41598-023-39372-3
3被引9阅读
引用收藏
分享

摘要

Human Epidermal Growth Factor Receptor-2 (HER2)-negative breast cancers (BCs) contain HER2-low and HER2-zero ones. HER2-low breast cancer has been receiving wide-spread concerns as the marvelous effect of novel anti-HER2 antibody-drug conjugates, however, the characteristic remains unknown. Our aim was to explore the differences of clinicopathological indicators and survival outcomes between HER2-low and HER2-0 breast cancers. We retrospectively analyzed 501 invasive breast cancer patients with complete data on HER2 status from 2017 to 2021 in our single center, of whom 415 HER2 negative patients were included for subsequent analysis. Each cohort was further divided into hormone receptor (HR) positive and HR negative subgroup. Clinicopathological factors and survival outcomes were collected and compared between HER2-low BCs and HER2-0 BCs. HER2-low BCs was obviously higher in HR positive BCs, with 277 (90.5%) HER2-low HR positive patients, 29 (9.5%) HER2-low HR negative patients, 68 (62.4%) HER2-0 HR positive patients and 41 (37.6%) HER2-0 HR negative patients (P<0.001). Significant differences between HER2-low BCs and Her2-0 BCs were observed in lymph node ratio (LNR) (mean rank, 215 vs. 188 P=0.014), estrogen receptor (ER)expression (90.5% vs. 62.4% P<0.001), progesterone receptor (PR) expression (84.3% vs. 56.9% P<0.001), Ki-67 expression (46.4% vs. 61.5% P<0.001), androgen receptor (AR) expression (68% vs. 50.5% P<0.001), adjuvant chemotherapy (69% vs. 79.8% P=0.03). HER2-low BCs had lower histological grade than HER2-0 BCs, with grade I-II (68.7% vs. 43.1%) and grade III (22.2% vs. 43.1%) P<0.01. No statistical differences were detected between the two groups for DFS and DDFS. Our results demonstrated that HR and AR status was closely related to HER2-low breast cancers. Further exploration about survival prognosis of HER2-low breast cancer is badly needed.

学科与关键词

关键词
MOLECULAR CHARACTERISTICSESTROGEN-RECEPTORTRASTUZUMABCHEMOTHERAPYRESISTANCEMECHANISMSEXPRESSIONLAPATINIB
相关
加载中…
  • Survival differences between HER2-0 and HER2-low-expressing breast cancer- A meta-analysis of early breast cancer patients
    Yang, Ciqiu; Zhang, Xiaoqi; Chen, Yitian; Li, Peiyong; Zhang, Junsheng; Xu, Aiqi; Huang, Na; Liang, Minting; Chen, Yilin; Wang, Kun*Critical Reviews in Oncology/Hematology, 2023, 185: 103962.被引 4
  • Clinicopathological characteristics of breast cancer patients with HER-2 low expression received neoadjuvant therapy
    Zhang, Shiyuan; Yu, Xiao; Xiu, Yuting; Qiao, Kun; Jiang, Cong*; Huang, Yuanxi*Oncology, 2024, 102(2): 122-130.
  • Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
    You, Shuhui; Gong, Chengcheng; Li, Yi; Xie, Yizhao; Li, Yumeng; Zhao, Yannan*; Wang, Biyun*Frontiers in Endocrinology, 2023, 14: 1270453.
查看全部 →

发表信息

论文状态
公开发表
期刊
Scientific Reports
发表日期
2023-07-18
卷期
第 13 卷, 第 1 期
页码
12382
DOI
10.1038/s41598-023-39372-3
语言
ENGLISH
成果收录
SCIE
资助标注
Natural Science Foundation of China [82173328]; Shenzhen High-level Hospital Construction Fund; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College, Shenzhen [SZ2020MS001, E010321023]

作者

  • Y

    Yang, Man (第一作者)

    chinese acad med sci · peking union med coll

  • S

    Sun, Jiale

    chinese acad med sci · peking union med coll

查看全部 7 位作者收起作者
  • L

    Liu, Liqiong

    chinese acad med sci · peking union med coll · southern med univ

  • K

    Kong, Xiangyi

    chinese acad med sci · peking union med coll

  • L

    Lin, Dongcai

    chinese acad med sci · peking union med coll

  • Z

    Zhou, Hong

    chinese acad med sci · peking union med coll

  • G

    Gao, Jidong (通讯)

    chinese acad med sci · peking union med coll

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417